LT3596B - Method for preparing crystaline torasemide - Google Patents

Method for preparing crystaline torasemide Download PDF

Info

Publication number
LT3596B
LT3596B LTIP898A LTIP898A LT3596B LT 3596 B LT3596 B LT 3596B LT IP898 A LTIP898 A LT IP898A LT IP898 A LTIP898 A LT IP898A LT 3596 B LT3596 B LT 3596B
Authority
LT
Lithuania
Prior art keywords
torasemide
modification
water
crystaline
preparing
Prior art date
Application number
LTIP898A
Other languages
English (en)
Lithuanian (lt)
Inventor
Fritz Topfmeier
Gustav Lettenbauer
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of LTIP898A publication Critical patent/LTIP898A/xx
Publication of LT3596B publication Critical patent/LT3596B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
LTIP898A 1985-08-17 1993-08-27 Method for preparing crystaline torasemide LT3596B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19853529529 DE3529529A1 (de) 1985-08-17 1985-08-17 Verfahren zur herstellung einer stabilen modifikation von torasemid

Publications (2)

Publication Number Publication Date
LTIP898A LTIP898A (en) 1995-03-27
LT3596B true LT3596B (en) 1995-12-27

Family

ID=6278766

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP898A LT3596B (en) 1985-08-17 1993-08-27 Method for preparing crystaline torasemide

Country Status (25)

Country Link
US (4) US4743693A (sv)
EP (1) EP0212537B1 (sv)
JP (2) JPS6245576A (sv)
KR (1) KR930009818B1 (sv)
AU (1) AU573454B2 (sv)
CA (1) CA1307277C (sv)
CS (2) CS259891B2 (sv)
DD (1) DD259858A5 (sv)
DE (2) DE3529529A1 (sv)
DK (1) DK162518C (sv)
ES (1) ES2001522A6 (sv)
FI (1) FI82189C (sv)
GR (1) GR862139B (sv)
HK (1) HK59994A (sv)
HU (1) HU195778B (sv)
IE (1) IE59237B1 (sv)
IL (1) IL79672A (sv)
LT (1) LT3596B (sv)
NO (1) NO170079C (sv)
NZ (1) NZ217172A (sv)
PL (1) PL146086B1 (sv)
PT (1) PT83186B (sv)
SU (1) SU1480766A3 (sv)
UA (1) UA7080A1 (sv)
ZA (1) ZA866151B (sv)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623620A1 (de) * 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
US5166162A (en) * 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
JP3586471B2 (ja) * 1991-06-25 2004-11-10 三菱ウェルファーマ株式会社 トラセミド含有医薬組成物
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US20030026835A1 (en) * 1999-02-15 2003-02-06 Sumitomo Pharmaceuticals Company Limited Tablets disintegrating rapidly in the oral cavity
CZ2002404A3 (cs) 1999-08-11 2002-06-12 Teva Pharmaceutical Industries Ltd. Polymorfní formy torsemidu
DE1292303T1 (de) 2000-02-17 2003-09-18 Teva Pharma Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
US6635765B2 (en) 2000-03-20 2003-10-21 Teva Pharmaceutical Industries, Ltd. Processes for preparing torsemide intermediate
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
IN192178B (sv) * 2001-08-03 2004-03-06 Ranbaxy Lab
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
PT1465890E (pt) * 2002-11-18 2007-05-31 Teva Pharma Lansoprazole estável contendo mais de 500 ppm, até cerca de 3000 ppm de água e mais de 200 ppm, até cerca de 5000 de álcool
US7678816B2 (en) * 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
US10178893B1 (en) * 2013-06-14 2019-01-15 Scott Bradley Baker Shoe
FR3018688A1 (fr) * 2014-03-19 2015-09-25 Virbac Utilisation de torasemide a faible dose dans une composition veterinaire
EP3031471A1 (en) 2014-12-12 2016-06-15 Ceva Sante Animale Veterinary composition for the treatment of pulmonary edema associated with heart failure in domestic animals
US12048677B2 (en) 2014-12-12 2024-07-30 Ceva Sante Animale Compositions and uses thereof for the treatment of heart failure in domestic animals
DK3173075T3 (en) * 2015-11-27 2019-01-21 Accupharma Spolka Z Ograniczona Odpowiedzialnoscia PHARMACEUTICAL COMBINATION PREPARATION OF ACE INHIBITOR AND LOOPDIURETIC
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) * 1860-11-13 Improvement in fire-escapes
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
GB1593609A (en) * 1978-01-31 1981-07-22 Christiaens Sa A Pyridine sulfonamides
LU85193A1 (fr) * 1984-01-31 1985-09-12 Christiaens Sa A Nouveaux derives de la 4-phenylaminopyridine,leur utilisation et leur preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. DUPONT ET AL.: "Structure d une seconde variété de la torasémide", ACTA CRYST., 1978, pages 2659 - 2662, XP002128456, DOI: doi:10.1107/S0567740878008900

Also Published As

Publication number Publication date
CS594586A2 (en) 1988-03-15
NO170079C (no) 1992-09-09
UA7080A1 (uk) 1995-06-30
DK385586A (da) 1987-02-18
NZ217172A (en) 1989-02-24
NO863305D0 (no) 1986-08-15
SU1480766A3 (ru) 1989-05-15
KR930009818B1 (ko) 1993-10-11
CS259891B2 (en) 1988-11-15
HK59994A (en) 1994-07-08
LTIP898A (en) 1995-03-27
DK385586D0 (da) 1986-08-13
DE3529529A1 (de) 1987-02-19
USRE34580E (en) 1994-04-05
US4822807A (en) 1989-04-18
DE3529529C2 (sv) 1987-05-27
JPH0415205B2 (sv) 1992-03-17
US4743693A (en) 1988-05-10
NO170079B (no) 1992-06-01
AU573454B2 (en) 1988-06-09
PL261052A1 (en) 1987-11-02
IE862179L (en) 1987-02-17
HU195778B (en) 1988-07-28
FI82189C (sv) 1991-02-11
DK162518B (da) 1991-11-11
AU6105586A (en) 1987-02-19
PT83186A (de) 1986-09-01
JPH02191255A (ja) 1990-07-27
EP0212537A1 (de) 1987-03-04
CS419991A3 (en) 1992-06-17
PL146086B1 (en) 1988-12-31
GR862139B (en) 1986-12-30
ZA866151B (en) 1987-04-29
EP0212537B1 (de) 1990-01-03
DD259858A5 (de) 1988-09-07
IL79672A0 (en) 1986-11-30
FI863305A (fi) 1987-02-18
ES2001522A6 (es) 1988-06-01
IE59237B1 (en) 1994-01-26
DK162518C (da) 1992-03-30
FI863305A0 (fi) 1986-08-15
FI82189B (fi) 1990-10-31
JPS6245576A (ja) 1987-02-27
DE3667970D1 (de) 1990-02-08
JPH0643400B2 (ja) 1994-06-08
NO863305L (no) 1987-02-18
HUT42069A (en) 1987-06-29
USRE34672E (en) 1994-07-26
CA1307277C (en) 1992-09-08
PT83186B (pt) 1988-07-01
KR870002076A (ko) 1987-03-30
IL79672A (en) 1990-01-18

Similar Documents

Publication Publication Date Title
LT3596B (en) Method for preparing crystaline torasemide
EP1421093B1 (en) Crystaline clindamycin free base
DE69915461T2 (de) Neue kristalline formen einer antiviralen benzimidazolverbindung
SU1410866A3 (ru) Способ получени стеарата ацетилэритромицина
DE202005021414U1 (de) Festes und kristallines Ibandronat-Natrium
CA1335590C (en) Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide
KR880002087B1 (ko) 항균성 나프티리딘 또는 퀴놀린 화합물의 염 및 그의 제조방법
US4442101A (en) Sesquihydrate of naphthyridine derivative, and process for the preparation thereof
DE3888913T2 (de) Kristallines beta-Lactam-Hydrat.
DE2326880C2 (de) 7-(D- α-Amino-1,4-cyclohexadien-1-ylacetamido)-desacetoxycephalosporansäuredihydrat
DE2500386A1 (de) 7-eckige klammer auf d-alpha-amino- alpha-(p-hydroxyphenyl)-acetamido eckige klammer zu-3-(1,2,3-triazol-5-yl-thiomethyl)-3-cephem.4.carbonsaeure-1,2-propylen-glykolat, verfahren zur herstellung und arzneimittel
CA1077502A (en) Microcrystalline 3-(alpha-acetonylbenzyl)-4-hydroxycoumarin (warfarin) compositions thereof methods of making and using
DE2522998A1 (de) Neues cephalosporinderivat, verfahren zu seiner herstellung und arzneimittel
US4438046A (en) Quaternary ammonium salts
JPH0543590A (ja) 結晶ラクチユロース三水和物とその製造法
DE3019885C2 (sv)
JPS604189B2 (ja) 抗菌剤およびその製法
CZ284738B6 (cs) Způsob přípravy izolované krystalické formy 3/2 hydrátu 7-[(7-(S)-amino-5-azaspirol[2,4]heptal-5-yl]-8-chlor-6-fluor-1-[(1R,2S)-2-fluorcyklopropyl]-4-oxo-1,4-dihydrochinolin-3-karboxylové kyseliny
NO764182L (sv)
KR20070034080A (ko) 1,24(ｓ)-디히드록시 비타민 ｄ2의 결정형
US3352859A (en) Process for improving crystal quality of a cephalosporin antibiotic
DE2430850C3 (de) Komplexverbindungen aus Digoxin und Dihydroxybenzolen, diese enthaltende pharmazeutische Zusammensetzungen und Verfahren zur Reinigung von Digoxin über diese Komplexverbindungen
US3591588A (en) Process for the preparation of 1-carboethoxyhydrazinophthalazine hydrochloride
CN117088925A (zh) 一种化合物晶型及其制备、组合物和用途
DE20321227U1 (de) Isostrukturelle Pseudopolymorphe von 9-Deoxo-9a-Aza-9a-Methyl-9a-Homoerythromycin A

Legal Events

Date Code Title Description
MK9A Expiry of a patent

Effective date: 20130827